Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between JPM and BIO through a dedicated one-to-one partnering system, bespoke matchmaking, and 100% alignment in research interests. Those attending will receive a significant competitive advantage by hearing insights on aligning data packages with expectations and by nurturing relationships with key contacts in a more exclusive setting.

Who Attends This Differentiated Business Development Initiative?

Global Pharma: Heads of Business Development, Search & Evaluation, and Asset Scouting for Neuroscience – comparing pipelines and enabling technologies to fuel future innovation.
Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain – seeking feedback, validation, and strategic partnerships with pharma and investors.
Investors & Venture Capital: Leaders focused on neuroscience investments with a higher risk appetite – looking for insights into pharma strategy and access to breakthrough opportunities.

With Novartis, Roche, Biogen, and AbbVie all signing deals in the last 6 months alone, now is the time to understand how to align with pharma’s interests, to capitalize on activity and appetite for best or first-in-class neuroscience assets.

Learn more: https://ter.li/o2406m